IAVI is working to ensure that AIDS vaccines are a global priority and that a future vaccine will be accessible to all who need it. In 2007, a new partnership between IAVI and Japanese researchers was launched to develop a recombinant Sendai Virus (Sev) vector vaccine, which has potential to elicit mucosal immunity in people. If successful, the SeV vector-based AIDS vaccine will be the first candidate developed in Japan that will advance to human clinical trials.
International AIDS Vaccine Initiative (IAVI), New York, NY, USA. 2 pp.